ResMed (RMD) PT Raised to $270 at Oppenheimer on Philips Recall
Tweet Send to a Friend
Oppenheimer analyst Suraj Kalia raised the price target on ResMed (NYSE: RMD) to $270.00 (from $240.00) while maintaining an Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
